DGAP-News: Evotec extends ongoing collaboration with CHDI Foundation
(firmenpresse) - DGAP-News: Evotec AG / Key word(s): Alliance
Evotec extends ongoing collaboration with CHDI Foundation
29.10.2012 / 07:27
---------------------------------------------------------------------
* Collaboration aims to accelerate development of drugs that slow the
progression of Huntington's disease (HD)
* Evotec eligible to receive up to USD 41 million
Hamburg, Germany | Oxford, UK | Los Angeles, CA, USA - 29 October 2012:
Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX) today announced that CHDI
Foundation, Inc. (CHDI), a privately-funded not-for-profit research
organisation dedicated to developing therapies for Huntington's disease
(HD), has extended its collaboration with Evotec until the end of 2015.
This contract extension could be worth up to USD 41 million in research
payments for Evotec.
The collaboration takes full advantage of Evotec's integrated drug
discovery platform and its proficiency in neurological research, including
its expertise in medicinal chemistry, in vitro and in vivo pharmacology,
and compound management.
Evotec and CHDI entered into this alliance in March 2006, and since then
the collaborative relationship has grown significantly. The extension of
this collaboration further validates Evotec's broad expertise in CNS drug
discovery and development.
'We are delighted that CHDI, an organisation dedicated solely to the quest
to discover novel drugs against Huntington's disease, continues to work in
partnership with Evotec,' said Dr Mario Polywka, Chief Operating Officer of
Evotec. 'This collaboration is an excellent example of how companies,
including foundations such as CHDI, can access Evotec's platform suite of
technologies, capabilities and strong disease biology expertise, to drive
their drug discovery efforts.'
'CHDI partners with a global network of investigators from the academic,
biopharmaceutical, and service sectors to execute our drug discovery and
development efforts,' said Dr Robert Pacifici, Chief Scientific Officer at
CHDI. 'Evotec represents one of our largest and longest standing
relationships with a contract research organisation. We are delighted that,
with the renewal of our contract, CHDI and Evotec will be able to continue
our productive interactions and drive our therapeutic programs forward.'
About Huntington's disease
Huntington's disease is a familial disease caused by a mutation in the
huntingtin gene. Each child of a parent with the mutation in the huntingtin
gene has a 50-50 chance of inheriting the mutation. As a result of carrying
the mutation, an individual's brain cells fail and die leading to cognitive
and physical impairments that, over the course of the disease,
significantly impair the individual's quality of life and ultimately cause
death. Symptoms of Huntington's disease, which generally develop in midlife
and become progressively more debilitating as time passes, can also develop
in infancy or old age. Once overt symptoms start, patients live for about
15 to 20 years. One person in 10,000 is believed to carry a mutation in the
huntingtin gene. There is currently no way to delay the onset of symptoms
or slow the progression of Huntington's disease.
FORWARD-LOOKING STATEMENTS: Information set forth in this press release
contains forward-looking statements, which involve a number of risks and
uncertainties. The forward-looking statements contained herein represent
the judgement of Evotec as of the date of this report. Such forward-looking
statements are neither promises nor guarantees, but are subject to a
variety of risks and uncertainties, many of which are beyond our control,
and which could cause actual results to differ materially from those
contemplated in these forward-looking statements. We expressly disclaim any
obligation or undertaking to release publicly any updates or revisions to
any such statements to reflect any change in our expectations or any change
in events, conditions or circumstances on which any such statement is
based.
Contact Evotec AG:
Dr Mario Polywka, Chief Operating Officer, Phone: +44.(0)1235.441676,
mario.polywka(at)evotec.com
End of Corporate News
---------------------------------------------------------------------
29.10.2012 Dissemination of a Corporate News, transmitted by DGAP - a
company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: Evotec AG
Manfred Eigen Campus / Essener Bogen 7
22419 Hamburg
Germany
Phone: +49 (0)40 560 81-0
Fax: +49 (0)40 560 81-222
E-mail: info(at)evotec.com
Internet: www.evotec.com
ISIN: DE0005664809
WKN: 566480
Indices: TecDAX
Listed: Regulierter Markt in Frankfurt (Prime Standard);
Freiverkehr in Berlin, Düsseldorf, Hamburg, Hannover,
München, Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------
190494 29.10.2012
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 29.10.2012 - 07:27 Uhr
Sprache: Deutsch
News-ID 196943
Anzahl Zeichen: 8373
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 340 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: Evotec extends ongoing collaboration with CHDI Foundation"
steht unter der journalistisch-redaktionellen Verantwortung von
Evotec AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
